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Since both HIV and HBV are endemic in sub-Saharan Africa and 
share routes of transmission, co-infection is common.1 As life 
expectancy with HIV has improved owing to widespread use of 
antiretroviral treatment (ART), the proportion of morbidity and 
mortality caused by non-AIDS-defining illnesses such as HBV is 
likely to increase.
Estimates of the prevalence of HBV infection among adults with 
HIV in South Africa have been around 5% in urban cohorts2,3 and 
20% in a cohort of goldminers from rural areas.1 It has therefore been 
suggested that co-infection rates are higher in rural than in urban 
areas in South Africa.4 We present prevalence data from a cohort of 
HIV-infected adults in rural Eastern Cape.
Methods
Madwaleni HIV Wellness and ART Programme is a public sector 
service in a deeply rural area of the Eastern Cape. ART delivery 
began in June 2005 and, by October 2009, about 4 000 adult 
patients had registered on the programme. About 2 000 patients had 
initiated ART; the remainder were not yet eligible for ART. Patient 
demographic and clinical data, including laboratory investigations, 
were prospectively entered into a database.
We sought to identify HBV co-infected patients so that we could 
motivate for them to receive tenofovir. All patients either established 
on ART or undergoing CD4 monitoring while not yet eligible for 
ART required 6-monthly routine blood tests. Over a 10-month 
period, testing for hepatitis B surface antigen (HBVsAg) was added as 
an additional test on all routine blood tests. Samples were processed 
within 48 hours by AxSYM HBsAg (V2) (Abbott Laboratories, 
Abbott Park, Illinois, USA).
Demographic details, HBVsAg results, ALT and CD4 count at 
the time of registration on the programme were extracted from the 
database. Statistical analysis was performed using STATA version 
10 (Stata Corp. College Station, TX). CD4 count and age were 
summarised using median and interquartile range as they were non-
normally distributed. ALT was categorised as either above or below 
the upper limit of the normal range at the programme laboratory 
(40 IU/l). A multivariate logistic regression model was constructed, 
using a stepwise forward fitting approach, adding first variables that 
appeared to be most strongly associated with HBVsAg status on 
univariate analysis. Age was included in the model based on an a 
priori decision.
Ethical approval was obtained from the University of Cape Town’s 
Faculty of Health Sciences Research Ethics Committee.
Results
Between December 2008 and October 2009, 1 765 adult patients 
were tested for HBVsAg, of whom126 were positive, giving an overall 
prevalence of 7.1%. The prevalence was 5.5% in females and 12.1% in 
males (chi-squared p<0.001). One thousand, one hundred and sixty-
nine (66%) had already commenced ART, and HBVsAg prevalence 
was similar in those on and off ART (6.6% v. 8.2%, chi-squared 
p=0.207). Patient HBVsAg status, demographic and laboratory 
variables and results of analysis are summarised in Table I.
On univariate analysis, ALT at baseline was associated with 
HBVsAg positivity (odds ratio (OR) 2.11, 95% confidence interval 
(CI) 1.32 - 3.38). After adjustment, the association remained but 
was weaker (OR 1.79, 95% CI 1.11 - 2.89, p=0.017), possibly because 
sex and ALT were strongly associated, with 21% of men and 11% 
of women having ALT>40 IU/l (chi-squared p<0.001). At baseline, 
89/116 (77%) of HBVsAg-positive patients had normal ALT.
After adjustment for age and baseline ALT, male sex remained 
strongly associated with HBVsAg positivity (OR 2.59, CI 1.68 - 4.00, 
p<0.001). Age was not associated with HBVsAg positivity.
Discussion
In this Eastern Cape cohort, the prevalence of HBV-HIV co-infection 
was 7.1%. This figure is lower than the 20% prevalence previously 
estimated in rural South Africa,1 but is similar to the estimated 
prevalence in urban cohorts.2,3 Male sex and abnormal baseline ALT 
were independent predictors of HBVsAg positivity in our cohort.
Previous estimates of rural co-infection rates may not be applicable 
to the rural population of South Africa as a whole. A study 
of goldminers in South Africa found a prevalence of 20%, but 
participants were drawn from a number of African countries, and 
94% were male.1
Male sex is a risk factor for HBV positivity in HIV-negative South 
Africans5 and is thought to be the result of either the observed 
prolonged replicative phase of the virus in boys or differences in the 
sexual behaviours of men and women.5,6 Our data are the first to 
suggest that male sex is also a risk factor for HBV positivity in HIV-
positive South Africans; further study is warranted to determine if the 
reasons for this correlation are similar to those in the HIV-negative 
population.Corresponding author: T Boyles (tomboyles@yahoo.com)
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The prevalence of hepatitis B virus (HBV) infection in 1 765 HIV-
positive patients in rural Eastern Cape was 7.1%. This is lower than 
the previously reported rural prevalence and is similar to urban 
prevalence. Male sex and baseline alanine aminotransferase (ALT) 
were significant predictors of HBV status. Most HBV-positive 
patients had normal baseline ALT, making ALT an insensitive 
screening test for HBV status.
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Studies have found ALT to be an unreliable marker of HBV status 
in HIV-positive adults, possibly because of the high prevalence of 
other factors that affect ALT, including opportunistic infections 
and drugs.1,3 We found an association between baseline ALT and 
HBV status in multivariate analysis. However, 77% of HBV-positive 
patients had a normal baseline ALT, so it is not a sensitive marker for 
HBVsAg positivity. Studies have shown that abnormal baseline ALT 
predicts high HBV viral load and risk of toxicity on ART.1 Baseline 
ALT may therefore be more useful as an addition to HBV testing than 
as a predictor of HBV status.
A limitation of this study is that HBVsAg was the only available 
measure of chronic HBV infection. A previous study has shown that 
detectable HBV viral load with negative HBVsAg (known as occult 
HBV infection) may account for two-thirds of all HBV infections, 
although the clinical implications of this are not well known.7 Patients 
were selected for the study by attending for routine blood tests, which 
might have biased the sample towards patients established on ART. 
However, the prevalence of HBV was similar among those on and off 
ART, suggesting that no important bias was introduced. Lamivudine 
is known to increase the rate of HBVsAg loss. Therefore, some 
patients on lamivudine might have cleared HBVsAg before testing.
We explored the association between ALT measured on entry into 
the treatment programme and a positive test for HBVsAg, as many 
patients had commenced an ART regimen containing lamivudine 
at the time of HBV testing. The maximum time from baseline 
measurement to HBV testing was 4 years. An important assumption 
is therefore that few HBV transmissions occurred in that time; this is 
reasonable, given the relatively short time period and that many HBV 
transmissions in South Africa are thought to occur in childhood.6
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Patients (N) 1 765 126 1 639 - -
Male
   N (%)
   (missing data 1)
440 (25) 53 (42) 387 (24) 2.64 (1.76, 3.95) 2.59 (1.68, 4.00) <0.001
Age (years)
    Median (IQR)    
    (missing data 277)
31.8 (26.3, 39.2) 32.0 (27.2, 39.4) 31.8 (26.1, 39.2) 1.01 (0.99, 1.02)* 0.99 (0.97, 1.01)† 0.482
CD4 cells/µl
   Median (IQR)
    (missing data 76)
207 (99 369) 176 (99 315) 210 (99 373) - -
ALT (IU/l)
   N (%)
   ≤40
   >40
1 400 (86) 89 (77) 1 311 (87) Referent Referent
222 (14) 27 (23) 195 (13) 2.11 1.79 0.017
    (missing data 144) (1.32, 3.38) (1.11, 2.89)
*Crude and adjusted analyses include 1 488 patients with full data set.
†Age is included in the model as a continuous variable. The OR is therefore for a one-year increase in age.
